دورية أكاديمية
Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion.
العنوان: | Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. |
---|---|
المؤلفون: | Van Acker HH; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium., Anguille S; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium., De Reu H; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium., Berneman ZN; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.; Division of Hematology, Antwerp University Hospital, Edegem, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium., Smits EL; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium.; Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Edegem, Belgium.; Center for Oncological Research (CORE), Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium., Van Tendeloo VF; Laboratory of Experimental Hematology, Tumor Immunology Group (TIGR), Faculty of Medicine and Health Sciences, Vaccine & Infectious Disease Institute (VAXINFECTIO), University of Antwerp, Antwerp, Belgium. |
المصدر: | Frontiers in immunology [Front Immunol] 2018 Apr 10; Vol. 9, pp. 658. Date of Electronic Publication: 2018 Apr 10 (Print Publication: 2018). |
نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
اللغة: | English |
بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Print ISSN: 1664-3224 (Print) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
مواضيع طبية MeSH: | Dendritic Cells/*immunology , Interleukin-15/*immunology , Intraepithelial Lymphocytes/*immunology , Leukemia, Myeloid, Acute/*immunology, Aged ; Aged, 80 and over ; Cancer Vaccines ; Cells, Cultured ; Coculture Techniques ; Female ; Humans ; Male ; Middle Aged |
مستخلص: | Dendritic cell (DC) vaccination can be an effective post-remission therapy for acute myeloid leukemia (AML). Yet, current DC vaccines do not encompass the ideal stimulatory triggers for innate gamma delta (γδ) T cell anti-tumor activity. Promoting type 1 cytotoxic γδ T cells in patients with AML is, however, most interesting, considering these unconventional T cells are primed for rapid function and exert meaningful control over AML. In this work, we demonstrate that interleukin (IL)-15 DCs have the capacity to enhance the anti-tumoral functions of γδ T cells. IL-15 DCs of healthy donors and of AML patients in remission induce the upregulation of cytotoxicity-associated and co-stimulatory molecules on the γδ T cell surface, but not of co-inhibitory molecules, incite γδ T cell proliferation and stimulate their interferon-γ production in the presence of blood cancer cells and phosphoantigens. Moreover, the innate cytotoxic capacity of γδ T cells is significantly enhanced upon interaction with IL-15 DCs, both towards leukemic cell lines and allogeneic primary AML blasts. Finally, we address soluble IL-15 secreted by IL-15 DCs as the main mechanism behind the IL-15 DC-mediated γδ T cell activation. These results indicate that the application of IL-15-secreting DC subsets could render DC-based anti-cancer vaccines more effective through, among others, the involvement of γδ T cells in the anti-leukemic immune response. |
References: | Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9692-7. (PMID: 26195801) PLoS One. 2011;6(6):e20952. (PMID: 21698118) N Engl J Med. 2015 Sep 17;373(12):1136-52. (PMID: 26376137) Oncoimmunology. 2015 Apr 1;4(8):e1021538. (PMID: 26405575) Blood. 2012 Sep 13;120(11):2269-79. (PMID: 22767497) J Immunother. 2014 Jul-Aug;37(6):321-30. (PMID: 24911793) Blood. 2011 Dec 22;118(26):6845-8. (PMID: 22067383) Immunotherapy. 2017 Jan;9(2):111-114. (PMID: 28128710) Oncotarget. 2015 Dec 29;6(42):44123-33. (PMID: 26675759) PLoS One. 2015 May 07;10(5):e0123340. (PMID: 25951230) Blood Cancer J. 2016 Jul 01;6(7):e441. (PMID: 27367478) Cytokine Growth Factor Rev. 2016 Oct;31:49-59. (PMID: 27325459) Leukemia. 2016 Aug;30(8):1749-52. (PMID: 26876593) Oncoimmunology. 2016 Apr 25;5(10 ):e1146843. (PMID: 27853633) J Immunol. 2016 Jan 15;196(2):645-54. (PMID: 26673141) Nat Rev Immunol. 2015 Nov;15(11):683-91. (PMID: 26449179) Pharmacol Ther. 2016 Feb;158:24-40. (PMID: 26617219) Leukemia. 2016 Feb;30(2):484-91. (PMID: 26239198) Sci Transl Med. 2016 Dec 7;8(368):368ra171. (PMID: 27928025) Front Immunol. 2015 Jan 26;6:15. (PMID: 25674089) Oncotarget. 2017 Feb 21;8(8):13652-13665. (PMID: 28099143) Blood. 2017 Oct 12;130(15):1713-1721. (PMID: 28830889) Blood Rev. 2013 Sep;27(5):209-16. (PMID: 23871358) Front Immunol. 2014 Dec 19;5:648. (PMID: 25566259) Haematologica. 2017 Jul;102(7):1227-1237. (PMID: 28302711) Immunol Cell Biol. 2017 Aug;95(7):620-629. (PMID: 28356569) Cell Immunol. 2015 Jul;296(1):10-21. (PMID: 25659480) Cancer Res. 2014 Sep 1;74(17):4772-82. (PMID: 24994712) Front Immunol. 2015 Jan 15;5:679. (PMID: 25642230) Oncotarget. 2017 May 25;8(34):56968-56979. (PMID: 28915646) Eur J Immunol. 2011 Feb;41(2):345-55. (PMID: 21268005) Semin Oncol. 2015 Aug;42(4):562-72. (PMID: 26320061) Pharmacol Rev. 2015 Oct;67(4):731-53. (PMID: 26240218) Expert Rev Clin Immunol. 2014 Jan;10(1):19-30. (PMID: 24308838) J Exp Med. 2000 Mar 6;191(5):771-80. (PMID: 10704459) J Immunol. 2010 Aug 1;185(3):1770-6. (PMID: 20592281) Nat Med. 2015 Aug;21(8):938-945. (PMID: 26193342) Front Immunol. 2014 Dec 11;5:636. (PMID: 25566249) Proc Natl Acad Sci U S A. 2018 Jan 30;115(5):1039-1044. (PMID: 29339503) J Immunol. 2012 Feb 15;188(4):1708-16. (PMID: 22250090) Blood. 2007 Aug 1;110(3):921-7. (PMID: 17403919) J Transl Med. 2009 Dec 18;7:109. (PMID: 20021667) Oncoimmunology. 2016 Sep 2;5(10 ):e1227902. (PMID: 27853652) Blood. 2011 Jul 28;118(4):992-1001. (PMID: 21633088) Nat Rev Immunol. 2013 Feb;13(2):88-100. (PMID: 23348415) Front Immunol. 2017 Jan 09;7:675. (PMID: 28119690) Hum Vaccin Immunother. 2013 Sep;9(9):1956-61. (PMID: 23778748) Eur J Immunol. 2004 Aug;34(8):2089-99. (PMID: 15259006) Curr Drug Targets. 2017;18(3):315-331. (PMID: 25981611) J Immunol. 2014 Mar 1;192(5):2237-43. (PMID: 24489097) Cancer Res. 2004 Nov 1;64(21):8062-7. (PMID: 15520217) Front Immunol. 2013 Dec 31;4:496. (PMID: 24427158) J Hematol Oncol. 2016 Sep 29;9(1):101. (PMID: 27686372) Cancer Immunol Res. 2017 Sep;5(9):812-820. (PMID: 28811289) J Clin Oncol. 2015 Jan 1;33(1):74-82. (PMID: 25403209) |
فهرسة مساهمة: | Keywords: acute myeloid leukemia; dendritic cell vaccination; immunotherapy; interleukin-15; γδ T cells |
المشرفين على المادة: | 0 (Cancer Vaccines) 0 (IL15 protein, human) 0 (Interleukin-15) |
تواريخ الأحداث: | Date Created: 20180426 Date Completed: 20190606 Latest Revision: 20210103 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC5902500 |
DOI: | 10.3389/fimmu.2018.00658 |
PMID: | 29692776 |
قاعدة البيانات: | MEDLINE |
تدمد: | 1664-3224 |
---|---|
DOI: | 10.3389/fimmu.2018.00658 |